Review top news and interview highlights from the week ending February 18, 2022.
Welcome to CGTLive’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.
The senior vice president of clinical development at Passage Bio discussed new data from the IMAGINE-1 trial presented at WORLDSymposium. He discussed the encouraging data in biomarkers, safety, and development seen so far in the 2 patients dosed.
The associate professor from UC San Diego discussed the gene-edited cell therapy that her lab has developed. She discussed the need for curative therapies in cystinosis and the potential of gene and cell therapies to fulfill this need.
Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.
The gene therapy AT845 (Astellas Pharma) has been well-tolerated in adult patients with late-onset Pompe disease (LOPD), according to positive interim safety data from the phase 1/2 FORTIS study (NCT04174105) presented at the 18th Annual WORLDSymposium.
P-PSMA-101, Poseida Therapeutics’ autologous chimeric antigen receptor (CAR) T-cell candidate, has shown promising anti-tumor activity in metastatic castration-resistant prostate cancer (mCRPC), with significant declines in prostate-specific antigen recorded